By reframing GLP-1 entry as a risk-management challenge, companies can position themselves not only for approval but for durable success in what will inevitably be a highly competitive and closely monitored market
doi: 10.1021/acs.molpharmaceut.7b00728 138 YamashitaTShimadaSGuoWSatoKKohmuraEHayakawaTet al
Only a minority of studies, that is, four in Parkinsons disease 52,53,54,55 , five in substance-use disorders 111,113,115,116,117 , one in psychotic disorders 144 and two in mood disorders 178,179,182 , assessed the cognitive and mental health effects of GLP-1RAs in non-diabetic, non-obese populations
She found out about the drug from a roommate
Changes in Kidney Function While Semaglutide is generally safe for the kidneys, it can still affect how they work, especially in people who are already at risk for kidney problems